BR9812484A - Terapia combinada para erradicação de hcv-rna detectável em pacientes com infecção crÈnica por hepatite c - Google Patents

Terapia combinada para erradicação de hcv-rna detectável em pacientes com infecção crÈnica por hepatite c

Info

Publication number
BR9812484A
BR9812484A BR9812484-6A BR9812484A BR9812484A BR 9812484 A BR9812484 A BR 9812484A BR 9812484 A BR9812484 A BR 9812484A BR 9812484 A BR9812484 A BR 9812484A
Authority
BR
Brazil
Prior art keywords
infection
rna
chronic hepatitis
alpha
interferon
Prior art date
Application number
BR9812484-6A
Other languages
English (en)
Inventor
Janice K Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27130070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9812484(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/938,033 external-priority patent/US6172046B1/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR9812484A publication Critical patent/BR9812484A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Patente de Invenção <B>"TERAPIA COMBINADA PARA ERRADICAçãO DE HCV-RNA DETECTáVEL EM PACIENTES COM INFECçãO CRÈNICA POR HEPATITE C"<D>. Apresenta-se o uso de ribavirina, alfa-interferon ou uma combinação de ribavirina e alfa-interferon para a produção de uma composição farmacêutica para o tratamento de um paciente com infecção crónica de hepatite C para erradicar HCV-RNA detectável, por um método que compreende a administração de uma quantidade eficaz de ribavirina, em conjunto com uma quantidade eficaz de alfa-interferon, onde o paciente falhou na resposta a um curso de tratamento prévio com terapia de alfa-interferon. As composições podem ser utilizadas em um método para tratamento de um paciente com infecção crónica de hepatite C para erradicar HCV-RNA detectável envolvendo uma terapia combinada que utiliza uma quantidade terapeuticamente eficaz de ribavirina e uma quantidade terapeuticamente eficaz de alfa-interferon durante um período de tempo desde 20 até 80 semanas.
BR9812484-6A 1997-09-21 1998-09-16 Terapia combinada para erradicação de hcv-rna detectável em pacientes com infecção crÈnica por hepatite c BR9812484A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/938,033 US6172046B1 (en) 1997-09-21 1997-09-21 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US93512397A 1997-09-22 1997-09-22
PCT/US1998/018488 WO1999015194A1 (en) 1997-09-21 1998-09-16 Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection

Publications (1)

Publication Number Publication Date
BR9812484A true BR9812484A (pt) 2000-09-19

Family

ID=27130070

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812484-6A BR9812484A (pt) 1997-09-21 1998-09-16 Terapia combinada para erradicação de hcv-rna detectável em pacientes com infecção crÈnica por hepatite c

Country Status (24)

Country Link
EP (3) EP0903148B1 (pt)
JP (1) JPH11152231A (pt)
KR (1) KR20010024188A (pt)
CN (1) CN1250283C (pt)
AR (1) AR013497A1 (pt)
AT (2) ATE206618T1 (pt)
AU (1) AU749924B2 (pt)
BR (1) BR9812484A (pt)
CA (1) CA2245938C (pt)
CO (1) CO4970691A1 (pt)
DE (2) DE69810822T2 (pt)
DK (2) DK1136075T3 (pt)
ES (2) ES2162393T3 (pt)
HK (2) HK1016505A1 (pt)
HU (1) HUP0100092A3 (pt)
IL (1) IL134428A0 (pt)
MY (1) MY117781A (pt)
NO (1) NO20001437L (pt)
NZ (1) NZ502740A (pt)
PE (1) PE119199A1 (pt)
PT (1) PT903148E (pt)
SK (1) SK3922000A3 (pt)
TW (1) TW568787B (pt)
WO (1) WO1999015194A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI277424B (en) * 1998-05-15 2007-04-01 Schering Corp Combination therapy for eradicating detectable NCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
WO2000037097A1 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-interferon alfa induction hcv combination therapy
EP1140143A2 (en) * 1998-12-18 2001-10-10 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
DE19919585A1 (de) 1999-04-29 2000-12-07 Cmi Ag Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen
AU2001259063A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20030036189A (ko) 2000-05-26 2003-05-09 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
EP1330468B1 (en) 2000-09-18 2007-08-01 Applied Research Systems ARS Holding N.V. Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
DE14169110T1 (de) 2002-06-28 2022-05-12 Centre National De La Recherche Scientifique -Cnrs- Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
JP2004155777A (ja) * 2002-10-16 2004-06-03 Asahi Kasei Pharma Kk Ｃ型慢性肝炎治療剤
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
US7429572B2 (en) 2003-05-30 2008-09-30 Pharmasset, Inc. Modified fluorinated nucleoside analogues
JP2007501806A (ja) * 2003-08-13 2007-02-01 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー ウィルス感染を治療する方法
ES2245248B1 (es) * 2004-06-09 2007-02-16 Universidad De Salamanca Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos.
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
BRPI0814363A2 (pt) 2007-07-25 2015-01-27 Biolex Therapeutics Inc Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
JP2012526149A (ja) 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
JP6073897B2 (ja) 2011-09-16 2017-02-01 ギリアド ファーマセット エルエルシー Ｈｃｖを処置するための方法
WO2013059638A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
ES2771458T3 (es) 2013-01-31 2020-07-06 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
PL3650014T3 (pl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Preparat złożony dwóch związków przeciwwirusowych
WO2015136455A1 (en) * 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection

Also Published As

Publication number Publication date
NZ502740A (en) 2002-10-25
HK1016505A1 (en) 1999-11-05
DK1136075T3 (da) 2003-04-28
CN1271292A (zh) 2000-10-25
DE69810822D1 (de) 2003-02-20
PE119199A1 (es) 1999-12-01
CO4970691A1 (es) 2000-11-07
HK1041440B (zh) 2003-09-05
NO20001437D0 (no) 2000-03-20
ES2186660T3 (es) 2003-05-16
EP1136075A1 (en) 2001-09-26
ATE206618T1 (de) 2001-10-15
EP0903148A2 (en) 1999-03-24
EP1136075B1 (en) 2003-01-15
CA2245938C (en) 2003-07-15
DE69801970T2 (de) 2002-06-13
EP0903148A3 (en) 1999-04-28
JPH11152231A (ja) 1999-06-08
WO1999015194A1 (en) 1999-04-01
CA2245938A1 (en) 1999-03-21
DK0903148T3 (da) 2001-12-17
TW568787B (en) 2004-01-01
MY117781A (en) 2004-08-30
DE69801970D1 (de) 2001-11-15
EP1317929A3 (en) 2003-07-02
AU9473798A (en) 1999-04-12
SK3922000A3 (en) 2000-10-09
KR20010024188A (ko) 2001-03-26
EP0903148B1 (en) 2001-10-10
EP1317929A2 (en) 2003-06-11
NO20001437L (no) 2000-03-20
AU749924B2 (en) 2002-07-04
DE69810822T2 (de) 2003-11-20
ATE230999T1 (de) 2003-02-15
ES2162393T3 (es) 2001-12-16
HUP0100092A2 (hu) 2001-05-28
PT903148E (pt) 2002-02-28
IL134428A0 (en) 2001-04-30
CN1250283C (zh) 2006-04-12
HUP0100092A3 (en) 2002-03-28
AR013497A1 (es) 2000-12-27
HK1041440A1 (en) 2002-07-12

Similar Documents

Publication Publication Date Title
BR9812484A (pt) Terapia combinada para erradicação de hcv-rna detectável em pacientes com infecção crÈnica por hepatite c
AR019551A1 (es) Uso de la ribavirina en combinacion con el interferon alfa para la fabricacion de un medicamento para la terapia de combinacion para erradicar hcv-rna detectable en pacientes no afectados a tratamiento antiviral que tienen infeccion de hepatitis c cronica
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
BR0312286A (pt) pró-medicamentos de 2&#39; e 3&#39; - nucleosìdeo modificado para tratamento de infecções por flaviviridae
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
BR9915546A (pt) Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica
CY1110078T1 (el) Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων
DE69426471T2 (de) Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR9907234A (pt) Polìmeros ligantes de gordura
KR930021178A (ko) 뼈 형성을 자극하는 약제
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
BR0011884A (pt) Método de tratamento da obesidade e condições comórbidas em um ser humano necessitando de tal tratamento, composto da fórmula i, produto contendo o composto da fórmula i, uso do composto da fórmula i, e, composição farmacêutica
BR9914570A (pt) Processo para o tratamento da esquizofrenia bem como agentes para o emprego neste processo
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
BR9812466A (pt) Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica
BR0113115A (pt) Tratamento de hepatite c com timosina, interferon e ribavirina
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica
BR9810095A (pt) Dispositivos para distribuição de droga e métodospara tratamento de infecções virais e microbianase de sìndromes de emaciação

Legal Events

Date Code Title Description
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART 36 DA LPI (LEI 9.279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.